Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MNOV [NASD]
MediciNova Inc.
Index- P/E- EPS (ttm)-0.12 Insider Own0.10% Shs Outstand24.22M Perf Week4.17%
Market Cap72.66M Forward P/E- EPS next Y-0.35 Insider Trans0.51% Shs Float20.43M Perf Month-21.26%
Income-3.40M PEG- EPS next Q-0.09 Inst Own9.80% Short Float1.51% Perf Quarter33.93%
Sales6.00M P/S12.11 EPS this Y71.20% Inst Trans9.00% Short Ratio2.10 Perf Half Y50.00%
Book/sh0.95 P/B3.16 EPS next Y- ROA-11.50% Target Price6.00 Perf Year30.43%
Cash/sh0.49 P/C6.11 EPS next 5Y20.00% ROE-13.60% 52W Range1.66 - 5.25 Perf YTD40.19%
Dividend- P/FCF- EPS past 5Y36.40% ROI-15.70% 52W High-42.86% Beta1.02
Dividend %- Quick Ratio11.50 Sales past 5Y- Gross Margin- 52W Low80.72% ATR0.23
Employees11 Current Ratio11.50 Sales Q/Q- Oper. Margin-56.70% RSI (14)44.38 Volatility4.69% 5.95%
OptionableNo Debt/Eq0.00 EPS Q/Q0.00% Profit Margin-56.70% Rel Volume0.08 Prev Close2.98
ShortableYes LT Debt/Eq0.00 EarningsAug 15 Payout- Avg Volume147.00K Price3.00
Recom1.00 SMA20-6.53% SMA50-10.31% SMA20025.52% Volume11,622 Change0.67%
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Nov-21-14 01:04PM  MEDICINOVA INC Financials EDGAR Online Financials
Nov-15-14 07:07PM  10-Q for MediciNova, Inc. Company Spotlight
Nov-14-14 09:01AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Nov-13-14 05:06PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-23-14 07:00PM  U.S. Centers for Disease Control and Prevention (CDC) Supports Recruitment for MediciNova's Clinical Trial of MN-166 (Ibudilast) in ALS GlobeNewswire +8.42%
Oct-22-14 07:00PM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
Oct-17-14 04:00PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -10.73%
Oct-08-14 07:00PM  MediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001 (tipelukast) in NASH GlobeNewswire +10.91%
Oct-06-14 07:00PM  MediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in Boston GlobeNewswire +12.67%
Sep-29-14 07:00PM  Overview of MediciNova's Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at The 13th Annual NEALS Meeting GlobeNewswire
Sep-23-14 07:00PM  MediciNova Provides Update on Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
Sep-07-14 07:00PM  MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence GlobeNewswire
Sep-01-14 07:00PM  MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) GlobeNewswire
Aug-28-14 04:00PM  MediciNova Rises on FDA's Nod on MN-166 Study Initiation Zacks
Aug-25-14 07:00PM  MediciNova to Initiate Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Aug-19-14 06:01AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online +5.56%
Aug-18-14 07:00PM  MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence GlobeNewswire
Aug-14-14 09:00AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Aug-13-14 05:00PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Aug-11-14 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Nonalcoholic Fatty Liver Disease GlobeNewswire
Aug-05-14 07:30AM  MediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDA GlobeNewswire
Jul-11-14 05:15PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and EDGAR Online
Jul-07-14 07:00PM  MediciNova to Present Data on MN-001 for the Treatment of NASH (Nonalcoholic Steatohepatitis) During the JDDW 2014 (Japan Digestive Disease Week 2014) GlobeNewswire
Jun-17-14 05:29PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu EDGAR Online
Jun-11-14 07:00PM  MediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary Fibrosis GlobeNewswire
May-09-14 10:33AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
May-08-14 05:05PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Apr-09-14 06:01AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offic EDGAR Online
Apr-08-14 07:00PM  MediciNova Appoints Yoshio Ishizaka to its Board of Directors GlobeNewswire +9.04%
07:00PM  MediciNova Announces Management Appointment GlobeNewswire
11:00AM  Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides Accesswire
Mar-28-14 06:07AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Mar-27-14 05:04PM  MEDICINOVA INC Files SEC form 10-K, Annual Report EDGAR Online
Mar-10-14 09:00AM  MEDICINOVA INC Files SEC form 8-K, Other Events EDGAR Online
Feb-25-14 04:47PM  MediciNova: Gestation Is Slow And Uncomfortable - Birth Is Sudden And Unexpected at Seeking Alpha
Jan-17-14 03:52PM  Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week at TheStreet
Jan-14-14 08:00AM  MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S. GlobeNewswire +32.09%
Jan-13-14 05:16PM  MEDICINOVA INC Files SEC form 8-K, Other Events EDGAR Online
Dec-30-13 06:10AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Dec-13-13 06:07AM  MediciNova (MNOV) Jumps: Stock Adds 22.2% in Session Zacks -10.98%
Nov-13-13 06:02AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offic EDGAR Online
Nov-11-13 06:00PM  MediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome GlobeNewswire
Nov-08-13 06:19AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online -6.11%
Nov-07-13 06:30PM  MediciNova Reports Third Quarter 2013 Results GlobeNewswire
05:17PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-18-13 03:19PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
Oct-16-13 05:00PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive A EDGAR Online +5.04%
05:00PM  MediciNova Appoints Yutaka Kobayashi to Its Board of Directors GlobeNewswire
04:30PM  InPlay: MediciNova appoints Geoffrey O'Brien as Vice President Briefing.com
04:30PM  MediciNova Appoints Geoffrey O'Brien as Vice President GlobeNewswire
Oct-06-13 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride GlobeNewswire
Sep-26-13 04:17PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
Aug-25-13 07:00PM  National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism GlobeNewswire
Aug-09-13 09:01AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Aug-08-13 05:30PM  MediciNova Reports Second Quarter 2013 Results GlobeNewswire
05:11PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Jul-30-13 09:02AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jul-18-13 07:00PM  MediciNova Announces Initiation of a Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis GlobeNewswire
Jul-17-13 09:03AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Jun-20-13 06:48PM  Nasdaq stocks posting largest volume increases AP -11.87%
Jun-19-13 05:15PM  MediciNova Presents MN-166 Data Zacks +31.13%
Jun-18-13 06:00PM  UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence GlobeNewswire
Jun-17-13 07:32AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu EDGAR Online
Jun-07-13 10:21AM  MEDICINOVA INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tr EDGAR Online
May-13-13 01:34PM  Monday Sector Leaders: Biotechnology, Drugs at Forbes +16.48%
May-09-13 11:13PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities EDGAR Online -26.78%
02:01AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
May-08-13 05:30PM  MediciNova Reports First Quarter 2013 Results GlobeNewswire +10.50%
10:10AM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Apr-18-13 06:35AM  MedicNova enters into 6M equity distribution agreement with Macquarie at theflyonthewall.com +6.72%
Apr-17-13 11:19PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
09:08AM  MEDICINOVA INC Files SEC form 8-K, Other Events EDGAR Online
Mar-29-13 02:02AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Mar-28-13 05:30PM  MediciNova Reports Fourth Quarter and Full Year 2012 Results GlobeNewswire
10:16AM  MEDICINOVA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
10:08AM  MEDICINOVA INC Files SEC form 10-K, Annual Report EDGAR Online
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166, a anti-inflammatory and neuroprotective agent, which has completed Phase 2 clinical trials for the treatment of neurological disorders; MN-221, a 2-adrenergic receptor agonist that has completed Phase 2b clinical trails for the treatment of acute exacerbations of asthma; MN-001, an orally bioavailable small molecule compound, which has completed Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; and MN-029, a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kobayashi YutakaDirectorNov 20Buy3.1913,00041,47038,000Nov 21 05:34 PM
Ishizaka YoshioDirectorNov 19Buy2.865,00014,3005,000Nov 20 08:45 PM
Kobayashi YutakaDirectorSep 11Buy2.9510,00029,50025,000Sep 11 05:44 PM
Kobayashi YutakaDirectorSep 03Buy2.6615,00039,84915,000Sep 04 06:50 PM